Showing results (61-70 of 871) with videos related to
Sort By:
Pageof 88
Progress in Biochemical Pharmacology|January 1, 1980
Serotonin receptor site in human platelets from control and chlorpromazine treated subjectsB Oppenheim, A Hefez, M B YoudimMovement Disorders : Official Journal of the Movement Disorder Society|April 16, 1998
Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamineM Gassen, A Gross, M B YoudimBritish Journal of Pharmacology|April 1, 1981
Ontogenesis of uptake and deamination of 5-hydroxytryptamine, dopamine and beta-phenylethylamine in isolated perfused lung and lung homogenates from ratsR R Ben-Harari, M B YoudimAnnals of the New York Academy of Sciences|July 21, 2001
Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022W Maruyama, M B Youdim, M NaoiJournal of Neural Transmission. Supplementum|January 1, 1994
Is selegiline neuroprotective in Parkinson's disease?M Gerlach, M B Youdim, P RiedererJournal of Neural Transmission. Supplementum|January 1, 1997
Mechanism of 6-hydroxydopamine neurotoxicityY Glinka, M Gassen, M B YoudimJournal of Neurology|September 19, 2000
MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategiesE Grünblatt, S Mandel, M B YoudimThe Journal of Clinical Endocrinology and Metabolism|March 17, 2000
Clinical review 112: Does serum growth hormone (GH) binding protein reflect human GH receptor function?T Amit, M B Youdim, Z HochbergMethods in Molecular Medicine|February 15, 2011
Oxidative stress indices in Parkinson's disease : biochemical determinationM B Youdim, N Drigues, S MandelAnnals of the New York Academy of Sciences|February 11, 2000
The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelatorsM B Youdim, E Grünblatt, S MandelPageof 88